Wednesday , March 29 2017

From the Editor

March, 2017

  • 28 March

    March 28, 2017


    It seems that the do-all, fix-all, be-all for kidney problems is either an ARB or ACE-I. We start patients on these medications at the first sign of elevated glucose levels regardless of their blood pressure levels, as they “protect” the kidneys. This is definitely true, but what do we do ...

    Read More »

Latest Articles

March, 2017

Test Your Knowledge

Question #878

The diabetes drug empagliflozin reduces all of the following CV risk factors except:


Answer: c. Low-density lipoprotein cholesterol

Explanation:  Empagliflozin is the only diabetes medication that is approved by the US Food and Drug Administration for both glycemic control and cardiovascular death risk reduction in adult patients with type 2 diabetes and cardiovascular disease. However, dose-related increases in low-density lipoprotein cholesterol have been observed in patients taking the drug. In clinical trials, low-density lipoprotein cholesterol increased by 2.3%, 4.6%, and 6.5% in patients treated with placebo, empagliflozin 10 mg, and empagliflozin 25 mg, respectively.

JARDIANCE® (empagliflozin) Prescribing Information. Accessed February 6, 2017.

Briand F, et al. Diabetes. 2016;65(7):2032-2038.   Briand F, et al. Diabetes. 2016;65(7):2032-2038.

Monthly Essentials: Empagliflozin and CV Death in Type 2 Diabetes


More Articles

March, 2017